Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi

Mario Cazzola, Luigino Calzetta, Clive P. Page, Paola Rogliani, Francesco Facciolo, Amadeu Gavaldà, Maria Gabriella Matera

Research output: Contribution to journalArticle

Abstract

Long-acting muscarinic receptor antagonists (LAMAs) and long-acting β2-adrenoceptor agonists (LABAs) cause airway smooth muscle (ASM) relaxation via different signal transduction pathways, but there are limited data concerning the interaction between these two drug classes on human bronchi. The aim of this study was to investigate the potential synergistic interaction between aclidinium bromide and formoterol fumarate on the relaxation of human ASM. We evaluated the influence of aclidinium bromide and formoterol fumarate on the contractile response induced by acetylcholine or electrical field stimulation (EFS) on human isolated airways (segmental bronchi and bronchioles). We analyzed the potential synergistic interaction between the compounds when administered in combination by using Bliss independence (BI) theory. Both aclidinium bromide and formoterol fumarate completely relaxed segmental bronchi pre-contracted with acetylcholine (Emax: 97.5±2.6% and 96.4±1.1%; pEC50 8.5±0.1 and 8.8±0.1; respectively). Formoterol fumarate, but not aclidinium bromide, abolished the contraction induced by acetylcholine in bronchioles (Emax: 68.1±4.5% and 99.0±5.6%; pEC50 7.9±0.3 and 8.4±0.3; respectively). The BI analysis indicated synergistic interaction at low concentrations in segmental bronchi (+18.4±2.7%; P

Original languageEnglish
Pages (from-to)135-143
Number of pages9
JournalEuropean Journal of Pharmacology
Volume745
DOIs
Publication statusPublished - Dec 15 2014

Fingerprint

Bronchi
Pharmacology
Acetylcholine
Bronchioles
Smooth Muscle
Muscarinic Antagonists
Muscle Relaxation
Muscarinic Receptors
Adrenergic Receptors
Electric Stimulation
Signal Transduction
aclidinium bromide
Formoterol Fumarate
Pharmaceutical Preparations

Keywords

  • COPD
  • Human bronchi
  • LABA
  • LAMA
  • Synergistic interaction

ASJC Scopus subject areas

  • Pharmacology
  • Medicine(all)

Cite this

Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. / Cazzola, Mario; Calzetta, Luigino; Page, Clive P.; Rogliani, Paola; Facciolo, Francesco; Gavaldà, Amadeu; Matera, Maria Gabriella.

In: European Journal of Pharmacology, Vol. 745, 15.12.2014, p. 135-143.

Research output: Contribution to journalArticle

Cazzola, Mario ; Calzetta, Luigino ; Page, Clive P. ; Rogliani, Paola ; Facciolo, Francesco ; Gavaldà, Amadeu ; Matera, Maria Gabriella. / Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. In: European Journal of Pharmacology. 2014 ; Vol. 745. pp. 135-143.
@article{d440ed088d4e413ea2795781f82a0e4e,
title = "Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi",
abstract = "Long-acting muscarinic receptor antagonists (LAMAs) and long-acting β2-adrenoceptor agonists (LABAs) cause airway smooth muscle (ASM) relaxation via different signal transduction pathways, but there are limited data concerning the interaction between these two drug classes on human bronchi. The aim of this study was to investigate the potential synergistic interaction between aclidinium bromide and formoterol fumarate on the relaxation of human ASM. We evaluated the influence of aclidinium bromide and formoterol fumarate on the contractile response induced by acetylcholine or electrical field stimulation (EFS) on human isolated airways (segmental bronchi and bronchioles). We analyzed the potential synergistic interaction between the compounds when administered in combination by using Bliss independence (BI) theory. Both aclidinium bromide and formoterol fumarate completely relaxed segmental bronchi pre-contracted with acetylcholine (Emax: 97.5±2.6{\%} and 96.4±1.1{\%}; pEC50 8.5±0.1 and 8.8±0.1; respectively). Formoterol fumarate, but not aclidinium bromide, abolished the contraction induced by acetylcholine in bronchioles (Emax: 68.1±4.5{\%} and 99.0±5.6{\%}; pEC50 7.9±0.3 and 8.4±0.3; respectively). The BI analysis indicated synergistic interaction at low concentrations in segmental bronchi (+18.4±2.7{\%}; P",
keywords = "COPD, Human bronchi, LABA, LAMA, Synergistic interaction",
author = "Mario Cazzola and Luigino Calzetta and Page, {Clive P.} and Paola Rogliani and Francesco Facciolo and Amadeu Gavald{\`a} and Matera, {Maria Gabriella}",
year = "2014",
month = "12",
day = "15",
doi = "10.1016/j.ejphar.2014.10.025",
language = "English",
volume = "745",
pages = "135--143",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

TY - JOUR

T1 - Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi

AU - Cazzola, Mario

AU - Calzetta, Luigino

AU - Page, Clive P.

AU - Rogliani, Paola

AU - Facciolo, Francesco

AU - Gavaldà, Amadeu

AU - Matera, Maria Gabriella

PY - 2014/12/15

Y1 - 2014/12/15

N2 - Long-acting muscarinic receptor antagonists (LAMAs) and long-acting β2-adrenoceptor agonists (LABAs) cause airway smooth muscle (ASM) relaxation via different signal transduction pathways, but there are limited data concerning the interaction between these two drug classes on human bronchi. The aim of this study was to investigate the potential synergistic interaction between aclidinium bromide and formoterol fumarate on the relaxation of human ASM. We evaluated the influence of aclidinium bromide and formoterol fumarate on the contractile response induced by acetylcholine or electrical field stimulation (EFS) on human isolated airways (segmental bronchi and bronchioles). We analyzed the potential synergistic interaction between the compounds when administered in combination by using Bliss independence (BI) theory. Both aclidinium bromide and formoterol fumarate completely relaxed segmental bronchi pre-contracted with acetylcholine (Emax: 97.5±2.6% and 96.4±1.1%; pEC50 8.5±0.1 and 8.8±0.1; respectively). Formoterol fumarate, but not aclidinium bromide, abolished the contraction induced by acetylcholine in bronchioles (Emax: 68.1±4.5% and 99.0±5.6%; pEC50 7.9±0.3 and 8.4±0.3; respectively). The BI analysis indicated synergistic interaction at low concentrations in segmental bronchi (+18.4±2.7%; P

AB - Long-acting muscarinic receptor antagonists (LAMAs) and long-acting β2-adrenoceptor agonists (LABAs) cause airway smooth muscle (ASM) relaxation via different signal transduction pathways, but there are limited data concerning the interaction between these two drug classes on human bronchi. The aim of this study was to investigate the potential synergistic interaction between aclidinium bromide and formoterol fumarate on the relaxation of human ASM. We evaluated the influence of aclidinium bromide and formoterol fumarate on the contractile response induced by acetylcholine or electrical field stimulation (EFS) on human isolated airways (segmental bronchi and bronchioles). We analyzed the potential synergistic interaction between the compounds when administered in combination by using Bliss independence (BI) theory. Both aclidinium bromide and formoterol fumarate completely relaxed segmental bronchi pre-contracted with acetylcholine (Emax: 97.5±2.6% and 96.4±1.1%; pEC50 8.5±0.1 and 8.8±0.1; respectively). Formoterol fumarate, but not aclidinium bromide, abolished the contraction induced by acetylcholine in bronchioles (Emax: 68.1±4.5% and 99.0±5.6%; pEC50 7.9±0.3 and 8.4±0.3; respectively). The BI analysis indicated synergistic interaction at low concentrations in segmental bronchi (+18.4±2.7%; P

KW - COPD

KW - Human bronchi

KW - LABA

KW - LAMA

KW - Synergistic interaction

UR - http://www.scopus.com/inward/record.url?scp=84919360274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919360274&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2014.10.025

DO - 10.1016/j.ejphar.2014.10.025

M3 - Article

C2 - 25446566

AN - SCOPUS:84919360274

VL - 745

SP - 135

EP - 143

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -